Sanguinarine, identified as a natural alkaloid LSD1 inhibitor, suppresses lung cancer cell growth and migration

Document Type : Original Article

Authors

1 Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, Henan Province, China

2 School of Pharmacy, Henan University of Chinese Medicine, Zhengzhou 450046, Henan province, China

Abstract

Objective(s): Lysine-specific demethylase1 (LSD1), an important class of histone demethylases, plays a crucial role in regulation of mammalian biology. The up-regulated LSD1 expression was frequently associated with progress and oncogenesis of multiple human cancers, including non-small cell lung cancer (NSCLC). Therefore, inhibition of LSD1 may provide an attractive strategy for cancer treatment. We investigated the effect of sanguinarine against lung cancer cells as a natural alkaloid LSD1 inhibitor. 
Materials and Methods: The inhibition properties of sanguinarine to the recombinant LSD1 were evaluated by a fluorescence-based method. Subsequently, assays such as viability, apoptosis, clonogenicity, wound healing, and transwell were performed on H1299 and H1975 cells after treatment with sanguinarine.
Results: Upon screening our in-house natural chemical library toward LSD1, we found that sanguinarine possessed a potent inhibitory effect against LSD1 with the IC50 value of 0.4 μM in a reversible manner. Molecular docking simulation suggested that sanguinarine may inactivate LSD1 by inserting into the binding pocket of LSD1 to compete with the FAD site. In H1299 and H1975 cells, sanguinarine inhibited the demethylation of LSD1, validating its cellular activity against the enzyme. Further studies showed that sanguinarine exhibited a strong capacity to suppress colony formation, inhibit migration and invasion, as well as induce apoptosis of H1299 and H1975 cells. 
Conclusion: Our findings present a new chemical scaffold for LSD1 inhibitors, and also provide new insight into the anti-NSCLC action of sanguinarine.

Keywords

References

1.    Yang L, Li N, Wang M, Zhang YH, Yan LD, Zhou W, et al. Tumorigenic effect of TERT and its potential therapeutic target in NSCLC. Oncol Rep 2021; 46: 182 .
2.    Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J, et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet 2009; 41:125-129.
3.    Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, et al. P53 is regulated by the lysine demethylase LSD1. Nature 2007; 449:105-108.
4.    Kontaki H, Talianidis I. Lysine methylation regulates E2F1-induced cell death. Mol Cell 2010; 39:152-160.
5.    Zhang J, Zhao D, Li Q, Du X, Liu Y, Dai X, et al. Upregulation of LSD1 promotes migration and invasion in gastric cancer through facilitating EMT. Cancer Manag Res 2019; 11:4481-4491.
6.    Derr RS, van Hoesel AQ, Benard A, Goossens-Beumer IJ, Sajet A, Dekker-Ensink NG, et al. High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells corr elate with decreased survival and increased relapse in breast cancer patients. BMC Cancer 2014; 14:604-615.
7.    Kashyap V, Ahmad S, Nilsson EM, Helczynski L, Kenna S, Persson JL, et al. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Mol Oncol 2013; 7:555-566.
8.    Ding J, Zhang ZM, Dong Q, Mi R, Xu KS, Yang XF, et al. [The influence and mechanisms of lysine-specific demethylase 1 (LSD1) on invasion and metastasis of c olon cancer cells]. Zhonghua Yi Xue Za Zhi 2017; 97:743-748.
9.    Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X, et al. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One 2012; 7:35065-35072.
10. Janardhan A, Kathera C, Darsi A, Ali W, He L, Yang Y, et al. Prominent role of histone lysine demethylases in cancer epigenetics and therapy. Oncotarget 2018; 9:34429-94448.
11. Li Y, Qian X, Lin Y, Tao L, Zuo Z, Zhang H, et al. Lipidomic profiling reveals lipid regulation by a novel LSD1 inhibitor treatment. Oncol Rep 2021; 46:233-247.
12. Feng J, Xu G, Liu J, Zhang N, Li L, Ji J, et al. Phosphorylation of LSD1 at ser112 is crucial for its function in induction of EMT and metastasis in b reast cancer. Breast Cancer Res Treat 2016; 159:443-456.
13. Zou ZK, Huang YQ, Zou Y, Zheng XK, Ma XD. Silencing of LSD1 gene modulates histone methylation and acetylation and induces the apoptosis of JeK o-1 and MOLT-4 cells. Int J Mol Med 2017; 40:319-328.
14. Chao A, Lin CY, Chao AN, Tsai CL, Chen MY, Lee LY, et al. Lysine-specific demethylase 1 (LSD1) destabilizes p62 and inhibits autophagy in gynecologic malignanc ies. Oncotarget 2017; 8:74434-74450.
15. Wei Y, Han T, Wang R, Wei J, Peng K, Lin Q, et al. LSD1 negatively regulates autophagy through the mTOR signaling pathway in ovarian cancer cells. Oncol Rep 2018; 40:425-433.
16. Jotatsu T, Yagishita S, Tajima K, Takahashi F, Mogushi K, Hidayat M, et al. LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer. Biochem Biophys Rep 2017; 9:86-94.
17. Lim SY, Macheleidt I, Dalvi P, Schafer SC, Kerick M, Ozreti L, et al. LSD1 modulates the non-canonical integrin ¦Â3 signaling pathway in non-small cell lung carcinoma cells. Sci Rep 2017; 7:10292-10303.
18. Jin Y, Ma D, Gramyk T, Guo C, Fang R, Ji H, et al. Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest. Biochem Biophys Res Commun 2019; 515:214-221.
19. Hong Y, Li X, Zhu J. LSD1-mediated stabilization of SEPT6 protein activates the TGF-¦Â1 pathway and regulates non-small-cel l lung cancer metastasis. Cancer Gene Ther 2021; 29:189-201.
20. Lu Z, Guo Y, Zhang X, Li J, Li L, Zhang S, et al. ORY-1001 suppresses cell growth and induces apoptosis in lung cancer through triggering HK2 mediated warburg effect. Front Pharmacol 2018; 9:1411-1419.
21. Zheng YC, Yu B, Chen ZS, Liu Y, Liu HM. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy. Epigenomics 2016; 8:651-666.
22. Abdulla A, Zhao X, Yang F. Natural polyphenols inhibit lysine-specific demethylase-1 in vitro. J Biochem Pharmacol Res 2013; 1:56-63.
23. Zheng YC, Shen DD, Ren M, Liu XQ, Wang ZR, Liu Y, et al. Baicalin, a natural LSD1 inhibitor. Bioorg Chem 2016; 69:129-131.
24. Fu Y, Liu W, Liu M, Zhang J, Yang M, Wang T, et al. In vitro anti-biofilm efficacy of sanguinarine against carbapenem-resistant Serratia marcescens. Biofouling 2021; 37:341-351.
25. Obiang-Obounou BW, Kang OH, Choi JG, Keum JH, Kim SB, Mun SH, et al. The mechanism of action of sanguinarine against methicillin-resistant Staphylococcus aureus. J Toxicol Sci 2011; 36:277-283.
26. Tsukamoto H, Kondo S, Mukudai Y, Nagumo T, Yasuda A, Kurihara Y, et al. Evaluation of anticancer activities of benzo[c]phenanthridine alkaloid sanguinarine in oral squamous cell carcinoma cell line. Anticancer Res 2011; 31:2841-2846.
27. Niu X, Fan T, Li W, Xing W, Huang H. The anti-inflammatory effects of sanguinarine and its modulation of inflammatory mediators from perit oneal macrophages. Eur J Pharmacol 2012; 689:262-269.
28. Su Q, Wang J, Liu F, Zhang Y. Blocking Parkin/PINK1-mediated mitophagy sensitizes hepatocellular carcinoma cells to sanguinarine-in duced mitochondrial apoptosis. Toxicol In Vitro 2020; 66:104840-104846.
29. Zheng YC, Duan YC, Ma JL, Xu RM, Zi X, Lv WL, et al. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. J Med Chem 2013; 56:8543-8560.
30. Zheng YC, Yu B, Jiang GZ, Feng XJ, He PX, Chu XY, et al. Irreversible LSD1 inhibitors: application of tranylcypromine and its derivatives in cancer treatment. Curr Top Med Chem 2016; 16:2179-2188.
31. Li ZR, Suo FZ, Guo YJ, Cheng HF, Niu SH, Shen DD, et al. Natural protoberberine alkaloids, identified as potent selective LSD1 inhibitors, induce AML cell differentiation. Bioorg Chem 2020; 97:103648-103655.
32. Lynch JT, Cockerill MJ, Hitchin JR, Wiseman DH, Somervaille TC. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demet hylase lysine-specific demethylase 1. Anal Biochem 2013; 442:104-106.
33. Fang J, Ying H, Mao T, Fang Y, Lu Y, Wang H, et al. Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresse s cell proliferation in human monocytic leukemia cells. Oncotarget 2017; 8:85085-85101.
34. Zhang X, Zhang X, Yu B, Hu R, Hao L. Oncogene LSD1 is epigenetically suppressed by miR-137 overexpression in human non-small cell lung can cer. Biochimie 2017; 137:12-19.
35. Fang Y, Yang C, Yu Z, Li X, Mu Q, Liao G, et al. Natural products as LSD1 inhibitors for cancer therapy. Acta Pharm Sin B 2020; 11:621-631.
36. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo) 2011; 64:525-531.
37. Majello B, Gorini F, Sacca CD, Amente S. Expanding the role of the histone lysine-specific demethylase LSD1 in cancer. Cancers (Basel) 2019; 11:324-338.
38. Zwergel C, Stazi G, Mai A, Valente S. Trends of LSD1 inhibitors in viral infections. Future Med Chem 2018; 10:1133-1136.
39. Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell 2018; 174:549-563.
40. Matsuda S, Baba R, Oki H, Morimoto S, Toyofuku M, Igaki S, et al. T-448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice. Neuropsychopharmacology 2019; 44:1505-1512.
41. Dai XJ, Liu Y, Xue LP, Xiong XP, Zhou Y, Zheng YC, et al. Reversible lysine specific demethylase 1 (LSD1) inhibitors: A promising wrench to impair LSD1. J Med Chem 2021; 64:2466-2488.
42. Lu W, Kang Y. Epithelial-mesenchymal plasticity in cancer progression and metastasis. Dev Cell 2019; 49:361-374.
43. Prabhu KS, Bhat AA, Siveen KS, Kuttikrishnan S, Raza SS, Raheed T, et al. Sanguinarine mediated apoptosis in non-small cell lung cancer via generation of reactive oxygen species and suppression of JAK/STAT pathway. Biomed Pharmacother 2021; 144:112358-112368.
44. Singh N, Sharma B. Toxicological effects of berberine and sanguinarine. Front Mol Biosci 2018; 5:21-27.
45. Yang X, Wang X, Gao D, Zhang Y, Chen X, Xia Q, et al. Developmental toxicity caused by sanguinarine in zebrafish embryos via regulating oxidative stress, apoptosis and wnt pathways. Toxicol Lett 2021; 350:71-80.
Iranian Journal of Basic Medical Sciences
Volume 25, Issue 6
June 2022
Pages 781-788

Files

Share

How to cite

Statistics